Matthew Porteus
Keine laufenden Positionen mehr
Vermögen: 8 Mio $ am 31.05.2024
Profil
Matthew Porteus is the founder of CRISPR Therapeutics AG, which was founded in 2013.
He is also the founder of Graphite Bio, Inc., which was founded in 2017.
Dr. Porteus's current job is as a Professor at Stanford University and as an Associate Professor at Stanford School of Medicine since 2010.
His former job was as an Assistant Professor at The University of Texas Southwestern Medical Center from 2003 to 2010.
Dr. Porteus's education includes an undergraduate degree from Harvard University and a doctorate from Stanford University.
Dr. Porteus is also the founder of Kamau Therapeutics, Inc...
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
1,97% | 01.02.2024 | 504 075 ( 1,97% ) | 8 Mio $ | 31.05.2024 |
Aktive Positionen von Matthew Porteus
| Unternehmen | Position | Beginn |
|---|---|---|
| Stanford School of Medicine | Corporate Officer/Principal | 01.10.2010 |
| Stanford University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Matthew Porteus
| Unternehmen | Position | Ende |
|---|---|---|
| The University of Texas Southwestern Medical Center | Corporate Officer/Principal | 01.08.2010 |
| LENZ THERAPEUTICS, INC. | Gründer | - |
| CRISPR THERAPEUTICS AG | Gründer | - |
Ausbildung von Matthew Porteus
| Harvard University | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
